GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy' [Seeking Alpha]
GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
US:NYSE Investor Relations:
gsk.com/en-gb/investors
Company Research
Source: Seeking Alpha
Play 16min Summary GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company's diversified portfolio includes vaccines, specialty medicines, and general medicines, with significant contributions from HIV and oncology treatments. Despite legal and regulatory challenges, GSK's strategic partnerships and international expansion, particularly in China, enhance its growth potential. GSK stock's valuation remains attractive with a low EV/EBITDA ratio, suggesting a buying opportunity as revenues are poised to grow into 2025. Risks include margin pressure and regulatory uncertainties, especially as margins declined from 24.3% in Q2 2023 to 16.5% in Q2 2024. digicomphoto GSK plc ( NYSE: GSK ) is a biopharmaceutical company with a long history of driving innovation in developing vaccines, specialty medicines, and general healthcare. The company has important pro
Show less
Read more
Impact Snapshot
Event Time:
GSK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GSK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GSK alerts
High impacting GSK plc American Depositary Shares (Each representing two Ordinary Shares) news events
Weekly update
A roundup of the hottest topics
GSK
News
- GSK plc (NYSE: GSK) was downgraded by analysts at Deutsche Bank Aktiengesellschaft from a "buy" rating to a "hold" rating.MarketBeat
- GSK plc (NYSE: GSK) was downgraded by analysts at Jefferies Financial Group Inc. from a "buy" rating to a "hold" rating. They now have a $39.50 price target on the stock, down previously from $53.00.MarketBeat
- GSK plc (NYSE: GSK) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.MarketBeat
- New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV DiseaseBusiness Wire
- GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV SeasonsBusiness Wire
GSK
Sec Filings
- 11/19/24 - Form 6-K
- 11/19/24 - Form 6-K
- 11/14/24 - Form 6-K
- GSK's page on the SEC website